Berlin Heart, Inc. appears in FDA records as the applicant for P160035, the premarket approval covering the EXCOR Pediatric Ventricular Assist Device. The SSED identifies the device generic name as Ventricular Assist Device (VAD), trade name EXCOR Pediatric Ventricular Assist Device, product code DSQ, and states the device was originally approved under Humanitarian Device Exemption H100004 before the PMA, with an FDA notice of approval dated June 6, 2017. The applicant address listed in that document is 200 Valleywood, Suite B100, The Woodlands, Texas. [7][1]
Documented product and classification
FDA records describe the regulated product as a ventricular assist bypass device in Class III, reviewed by the Cardiovascular advisory committee, under product code DSQ. The SSED names the device as the EXCOR Pediatric Ventricular Assist Device and records its earlier Humanitarian Device Exemption, H100004. The same document notes that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information. [7][6][1]
The SSED references a 2016 publication on Berlin Heart EXCOR use in patients with congenital heart disease by Morales, Zafar and Almond et al., and the FDA PMA page links to a ClinicalTrials.gov study record. These references appear in the filing materials; the public documents do not provide outcome data from them. [7][8]
Recent supplement activity
The linked record sample lists five P160035 supplements decided in October 2026. S054, received November 21, 2025 and decided October 30, 2026, was approved for a change in the buffer solutions used during the blood pump coating process. S056, received November 26, 2025 and decided October 14, 2026, was approved for the addition of a new polyol material supplier. S057, received March 3, 2026 and decided October 1, 2026, was approved for implementing dynamic viscosity measurement with specification limits for the silicone coating solution used in manufacturing EXCOR cannulae and connecting/extension sets. [1][4][5]
Two further entries in the sample carry the OK30 decision code. S060, received September 24, 2026 and decided October 23, 2026, covers supplier and manufacturing process changes to the cannula silicone sheeting. S061, received September 29, 2026 and decided October 28, 2026, covers manufacturing facility modifications at the Berlin Heart GmbH facility in Berlin, Germany for production of the EXCOR Pediatric Ventricular Assist Device. [3][2]
How the filings are counted
The supplied collection contains seven linked PMA records, with decision counts of five APPR and two OK30. The smaller record sample contains five entries, with sample decision counts of three APPR and two OK30. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1][2][3][4][5]
The FDA PMA page for P160035 lists supplement numbers including S051, S052, S055, S056, S057, S058, S059 and S060, and shows a page update date of October 26, 2026. The page carries a note that the device has supplements and that the description, function or indication may have changed. [6]
Applicant identity and scope limits
Berlin Heart, Inc. is the applicant named on the P160035 filings, with the Woodlands, Texas address appearing in FDA records. S061 separately refers to manufacturing facility modifications at the Berlin Heart GmbH facility in Berlin, Germany. The public documents do not establish a parent, brand or ownership relationship between these entities, and the FDA filing address is not treated here as a headquarters designation. [1][2][7]
The public documents do not document company revenue, employee counts, commercial availability, certifications, customers or clinical outcomes. Any statement beyond the identified product, its classification and the listed supplement scopes is not supported by these documents. [7][6]







